m110

M-110 is a highly selective, ATP-competitive inhibitor of PIM kinases, showing a preference for PIM-3 (IC50=47 nM), and inhibits PIM-1 and PIM-2 with similar IC50s of 2.5 μM. M-110 also inhibits the proliferation of prostate cancer cell lines with IC50s of 0.6 to 0.9 μM.

AM11095, a known NAAA inhibitor, has demonstrated potential as a cancer therapeutic agent.

KM11060 is a novel corrector of the F508del-CFTR trafficking defect, Correcting F508del-CFTR trafficking, increasing the amount of functional CFTR at the plasma membrane.

Efinaconazole (KP-103)(KP-103) is an Azole Antifungal currently under development as a topical treatment for onychomycosis.

Lanoconazole is an antifungal imidazole drug used primarily for the treatment of fungal skin infections that is potent and orally available. It acts by inhibiting the synthesis of ergosterol in fungal cell membranes, increasing the permeability of fungal cell membranes, leading to cell lysis and death. Lanoconazole exhibits potent antifungal activity against a wide range of pathogenic fungi including yeast, dermatophytes, dermatiaceous fungi, dimorphic fungi, Aspergihs spp., and Candida spp..